The pivotal role of the anti-EGFR Fab arm to mediate ADCC activation by BiXAbTM and the better capacity of 2MAbs with an EGFR valence to induce ADCC, compared with BiXAbTM, could be explained by the higher EGFR expression in the pancreatic cancer cell lines used in the present study. This evidence concerns the gene EGFR and pancreatic neoplasm.